GLOPID-R

ISCIIIISCIII participates in an international study revealing genetic variants associated with severe COVID-19 and possible therapeutic targets

An international study led by the University of Edinburgh with the participation of Spanish research centers including the National Institute of Health Carlos III (ISCIII), a GloPID-R member, was published on May 17, 2023 in Nature.

‘GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19’ presents the findings of a GenOMICC genome-wide association study (GWAS) identifying 49 genetic variants underlying critical COVID-19, 16 of which have not been reported previously. It also highlights molecular mechanisms that alter clinical outcomes in COVID-19 and may have direct therapeutic relevance.

The ISCIII contribution to the study included financing through the COVID-19 Fund and Strategic Action in Health, co-financed by the European Union; the participation of the Consortium for Biomedical Research Network (CIBER); and the collaboration of researchers from its National Microbiology Centre.

Read more

EU Flag

The GloPID-R Secretariat is a project which receives funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101094188.